近视巩膜重塑:机制与治疗途径
本综述聚焦高度近视中巩膜在眼轴过度延长下的生物力学削弱及其与后巩膜葡萄肿、近视性黄斑变性、视网膜脱离、白内障和青光眼等并发症风险的关系。文章概述巩膜细胞外基质组成、胶原组织、生物力学完整性与信号通路的变化,并讨论后巩膜加固、交联、药物与组织工程等研究性巩膜治疗及其机制、临床前与临床证据和转化障碍。
要点
- 高度近视因眼轴过度延长致巩膜生物力学削弱,增加多种致盲并发症风险。
- 现有近视管理主要延缓儿童期眼轴增长,高度近视成人仍面临并发症风险。
- 靶向强化巩膜的治疗尚处实验阶段,转化受后极部安全递送与疗效标准缺失制约。
核心结论
- 巩膜既是近视病理的关键驱动因素,也是有前景的治疗靶点,但相关疗法仍属实验性。
- 需要生物力学、分子生物学与治疗创新的跨学科合作,才能将实验性方法转化为临床可行治疗。
研究设计与样本
- 本文为综述,围绕巩膜在近视进展中的作用、研究性巩膜治疗及其转化障碍进行论述。
- 综述涵盖后巩膜加固技术、交联方式、药理策略与组织工程方法,并讨论其机制、临床前与临床证据。
主要发现
- 高度近视是全球视力损害的主要原因,由眼轴过度延长驱动巩膜生物力学削弱。
- 高度近视增加后巩膜葡萄肿、近视性黄斑变性、视网膜脱离、白内障和青光眼等并发症风险。
- 偏振敏感光学相干断层扫描、布里渊显微镜和超声弹性成像等成像与在体生物力学评估进展,有望用于早期风险分层和治疗监测。
临床怎么用
- 现有近视管理策略以减缓儿童期眼轴延长为目标,高度近视患者成年后仍需关注视力威胁性并发症。
- 针对薄弱巩膜的靶向治疗目前仍属实验性,临床决策应关注后极部安全递送与视网膜安全性。
- 缺乏将生物力学强化与功能获益联系起来的标准化结局指标,是相关疗法转化的关键障碍。
局限性
- 综述指出后极部安全递送、视网膜安全性及标准化结局指标缺失等转化障碍。
- 研究性巩膜治疗仍属实验性,尚缺乏将其转化为临床可行治疗的充分证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High myopia is the leading cause of visual impairment worldwide, driven by excessive axial elongation resulting in biomechanical weakening of the sclera, and increasing the risk of complications such as posterior staphyloma, myopic macular degeneration, retinal detachment, cataract, and glaucoma. Conventional myopia management strategies aim to slow axial elongation in childhood, leaving patients with high myopia at risk of vision-threatening complications as they age. For these individuals, targeted therapies that strengthen the weakened sclera represent a promising, yet still experimental, approach. This review provides an overview of the role of the sclera in myopia progression, emphasizing changes in extracellular matrix composition, collagen organization, biomechanical integrity, and signaling pathways. Investigational scleral therapies are discussed, including posterior scleral reinforcement techniques, crosslinking modalities, pharmacological strategies, and tissue engineering approaches, with discussion of their mechanisms, preclinical and clinical evidence, and translational challenges. Particular attention is given to translational barriers, such as safe delivery to the posterior pole, retinal safety, and the absence of standardized outcome measures that link biomechanical reinforcement to functional benefit. Advances in imaging and in vivo biomechanical assessment, such as polarization-sensitive optical coherence tomography, Brillouin microscopy, and ultrasound-based elastography, hold promise for earlier risk stratification and treatment monitoring. By integrating insights from biomechanics, molecular biology, and therapeutic innovation, this review highlights the sclera as both a key driver of myopia pathology and a promising therapeutic target. Continued interdisciplinary collaboration will be essential to translate these experimental approaches into clinically viable treatments capable of reducing the growing burden of high myopia worldwide.
引用
- Vogels DHJ, Ma Q, Boote C, et al. Scleral remodeling in myopia: mechanisms and therapeutic approaches. Prog Retin Eye Res. 2026. PMID: 42309346. doi:10.1016/j.preteyeres.2026.101486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。